Duchesnay USA Announces Partnership With TV Personality And Expectant Mom Emily Maynard Johnson To Create Awareness About Morning Sickness And Treatment Options
Empowering Women with Morning Sickness: Don't Suffer in Silence
Diclegis® (doxylamine succinate/pyridoxine hydrochloride) is the only FDA-approved medication to treat Morning Sickness after diet and lifestyle changes have failed.
ROSEMONT, PA, June 28, 2016 /PRNewswire/ - Duchesnay USA is a pharmaceutical company devoted to safeguarding the health and well-being of expectant mothers and their unborn babies. Today, the company announced a partnership with TV Personality and New York Times Best-Selling Author, Emily Maynard Johnson, to raise awareness about Morning Sickness and treatment options.
Best known for her appearance on "The Bachelor" and "The Bachelorette", Emily is a wife, mother of two and lifestyle expert. Upon learning she was expecting her third child, Emily was thrilled. However, she became concerned about juggling her family, personal life and career, while experiencing Morning Sickness, which she had struggled with throughout her previous pregnancies.
"This time around, it was really important for me to find a way to feel better and enjoy my pregnancy", said Emily.
After modifying her diet, her lifestyle and trying various prescription treatment options without success, Emily turned to Twitter, asking for suggestions to help manage her Morning Sickness. That's where she learned about Diclegis®, the only FDA-approved and only Pregnancy Category A prescription medication for Morning Sickness after diet and lifestyle changes have failed.
"I'm grateful to have found Diclegis®, which has helped me manage my Morning Sickness. I encourage all expectant moms who have Morning Sickness to stop suffering in silence! Ask your healthcare provider if Diclegis® is right for you like I did", advises Emily.
Emily is among the estimated 85% of all pregnant women who experience Morning Sickness2 each year. Because nausea and vomiting commonly occur even before the first prenatal appointment, many pregnant women are left undertreated.
Dean Hopkins, Duchesnay USA's General Manager, stated, "We are pleased to welcome Emily to the Duchesnay USA family to help empower women. By sharing her story, Emily is helping to build awareness that Morning Sickness is a treatable medical condition and that Diclegis® is working for her".
For more information about Morning Sickness and Diclegis®, visit www.Diclegis.com.
For US Residents Only.
Indication
Diclegis® is a prescription medicine used to treat nausea and vomiting of pregnancy in women who have not improved with change in diet or other non-medicine treatments.
Limitations of Use
Diclegis® has not been studied in women with hyperemesis gravidarum.
Important Safety Information
Do not take Diclegis® if you are allergic to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any of the ingredients in Diclegis. You should also not take Diclegis® in combination with medicines called monoamine oxidase inhibitors (MAOIs), as these medicines can intensify and prolong the adverse central nervous system (CNS) effects of Diclegis®.
The most common side effect of Diclegis® is drowsiness. Do not drive, operate heavy machinery, or participate in other activities that need your full attention unless your healthcare provider says that you may do so.
Do not drink alcohol, or take other CNS depressants such as cough and cold medicines, certain pain medicines, and medicines that help you sleep while you take Diclegis®. Severe drowsiness can happen or become worse causing falls or accidents.
Diclegis® should be used with caution in women who have certain medical conditions, such as asthma (1), or eye (2, 3), stomach (4, 5, 6) or bladder problems. Tell your healthcare provider about all of your medical conditions so he/she can assess if Diclegis® is right for you.
It is not known if Diclegis® is safe and effective in children under 18 years of age. Keep Diclegis® and all medicines out of the reach of children.
Diclegis® is a delayed-release formulation, so signs of overdose may not appear right away. If you take too much Diclegis® (overdose), you may have the following symptoms: restlessness, dry mouth, the pupils of your eyes become larger (dilated), sleepiness, dizziness, confusion, fast heart rate, seizures, muscle pain or weakness, and sudden and severe kidney problems. If you have these symptoms and they are severe, they may lead to death. Stop taking Diclegis®, call your healthcare provider or go to the nearest hospital emergency room right away. For more information about overdose treatment, call your poison control center at 1-800-222-1222.
Diclegis® is intended for use in pregnant women.
Tell your healthcare provider about all of your medical conditions, including if you are breastfeeding or plan to breastfeed. Diclegis® can pass into your breast milk and may harm your baby. You should not breastfeed while using Diclegis®.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
For additional important safety information, please see full Prescribing and Patient Information at www.diclegis.com. This information is not intended to replace discussions with your healthcare provider.
###
About Nausea and Vomiting of Pregnancy (NVP)
Nausea and vomiting of pregnancy (NVP), or morning sickness, up to 85 percent of pregnant women.2 NVP can present differently for each woman, the symptoms include: nausea, gagging, retching, dry heaving, vomiting, and odor and/or food aversion.3 For most pregnant women, symptoms generally cease at approximately 16 to 20 weeks.4 However, some women can experience symptoms throughout their pregnancy.5
About Diclegis
Diclegis (doxylamine succinate 10 mg, pyridoxine hydrochloride 10 mg) delayed-release tablets are the only FDA-approved prescription treatment for nausea and vomiting of pregnancy (NVP) in women who do not respond to conservative management. Diclegis has proven to be a safe and effective treatment option for NVP and received Pregnancy Category A status, which means the results of controlled studies have not shown an increased risk to an unborn baby.6
About Duchesnay USA
Duchesnay USA is a unique healthcare company devoted to safeguarding the health and well-being of expectant mothers and their unborn babies. Its affiliate company, Duchesnay Inc., was founded in 1970 in Canada. The family-owned company realigned its business in 1992 to focus specifically on pregnant women after a family member experienced a very difficult pregnancy. Duchesnay's mission is to develop pharmacological solutions to reduce the symptoms of nausea and vomiting during pregnancy (NVP). Duchesnay USA was established in Rosemont, Pennsylvania in 2011 to pursue that same mission. Realizing a lack of sufficient information on medications for use in pregnancy, Duchesnay strives today to ensure that expectant women who require pharmacological treatments have access to proper medical advice and therapies that are safe for them and their unborn babies. For more information on Duchesnay USA, please visit www.DuchesnayUSA.com.
1 Diclegis Prescribing Information. Duchesnay USA. 2013.
2 Whitehead, SA, Andrews, LR, Chamberlain, VP. Characterisation of Nausea and Vomiting in Early Pregnancy: A Survey of 1000 Women. Journal of Obstetrics and Gynaecology. 1992; 12: 384-369.
3 Clark S, Costantine M, Hankins GDV. Review of NVP and HG and early pharmacotherapeutic Intervention. Obstetrics and Gynecology International Volume. 2012.
4 Gadsby, R, Barnie-Adshead, A, Jagger, C. A Prospective Study of Nausea and Vomiting During Pregnancy. British Journal of General Practice. 1993; 43: 245-248.
5 Jarnfelt-Samsioe, A, Samsio, G, Velinder, G. Nausea and Vomiting in Pregnancy A Contribution to Its Epidemiology. Gynecologic and Obstetric Investigation. 1983; 16: 221-229.
6 Department of Health and Human Services, Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Federal Register. 2008; 73 (104):30831-68.
SOURCE Duchesnay USA
